Over time, life expectancy has increased and disease patterns have shifted globally (1,2). This major success is attributable to public health interventions, as well as substantial improvements in and accessibility of healthcare. Our understanding of risk factors for early onset and progression of noncommunicable diseases has improved substantially. Within the last century, population-based research established the role of lifestyle determinants of disease including smoking, low physical activity, and nutrition. Twenty-first century research has made major breakthroughs by characterizing the genetic contribution to diseases, establishing polygenic risk scores, and quantifying environmental exposures such as air pollution as major contributors to the global burden of disease. Nevertheless, the COVID-19 pandemic showed that we were ill prepared for dealing with novel emerging infectious diseases. Now in the aftermath of the COVID-19 pandemic, we realize the imminent need for high quality, prospective, population-based cohort data and public health surveillance of non-communicable and infectious diseases (3).Europe has a longstanding tradition of successfully implementing and maintaining populationbased cohorts over decades. Large-scale cohort studies, in particular studies with more than 100,000 participants, enable researchers to address the complexity of risk and protective factors jointly, to understand underlying joint disease mechanisms, and to assess the incidence of complex diseases and their subtypes prospectively. Furthermore, they allow for the assessment of the effectiveness of health promotion and primary prevention for the decades to come. Establishing a large-scale cohort is an enormous and multi-disciplinary endeavor and requires substantial planning that builds upon experience. Large-scale cohort studies such as, for example, the UK Biobank (4), Lifelines (5), Constances (6), or the German National Cohort (NAKO) (7) showed that it is feasible to recruit and characterize large population groups (Figure 1).The concept for the Swiss Cohort & Biobank described in the white paper by Probst-Hensch et al.(3) puts forward a timely and ambitious concept. The Swiss Cohort & Biobank is designed to address specific cultural, ethnic, social, and environmental circumstances to optimally promote health and tailor efforts towards the Swiss healthcare system. The concept builds upon ongoing cohort studies in Switzerland and proposes important innovation, while building upon successful large-scale cohorts within Europe to ensure comparability and interoperability of data. The innovations include recruitment from birth to old age at baseline, implementation of novel eHealth tools, and citizens' involvement during planning and execution to overcome difficulties in response rates. The scientists spearheading the efforts represent major academic institutions, universities, and societies of public health and have all the needed scientific experiences to embark on such a challenging endeavor. It will be important to ensure...